Torre et al. [99] found that when human non-Hodgkin’s lymphoma cell lines responded poorly to CD19 CAR-T cell therapy gradually, HDACi (vorinostat, also known as SAHA or panobinostat) reversed the resistance to CD19 CAR-T cell therapy. The gene discussed is CD19; the disease is non-Hodgkin lymphoma.